首页
>
>
投稿咨询
微信添加科研助理

了解相关问题

加急服务
微信添加科研助理

了解相关问题

EXPERT OPINION ON INVESTIGATIONAL DRUGS
ISSN：1354-3784

EXPERT OPINION ON INVESTIGATIONAL DRUGS

EXPERT OPIN INV DRUG
学科领域：医学
是否预警：不在预警名单内
是否OA：否
录用周期：较慢,6-12周
新锐分区：医学3区
年发文量：99
影响因子：4.1
JCR分区：Q1

基本信息

《研究药物专家意见》（ISSN 1354-3784 [印刷版]，1744-7658 [电子版]）是一份MEDLINE索引的、同行评审的国际期刊，发表关于药物临床前和早期临床开发的综述文章和原创论文，为未来的发展提供专家意见。编辑欢迎：综述涵盖药物或药物类别的特定适应症的临床前到II期数据，及其对未来治疗策略的潜在影响药物评价综述特定药物的临床和药理学数据原创研究论文报告I期和II期临床试验中药物的临床研究结果受众包括制药行业的科学家、管理人员和决策者，以及其他密切参与研发的人员。
1354-3784SCIE/Scopus收录
4.1
点击查看最新影响趋势>
4.3
新
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
否
N/A
新
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q1
79/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科：PHARMACOLOGY & PHARMACY
SCIE
Q2
89/353
94
99
点击查看年发文量趋势图>
3%一般较慢,6-12周-医学-药学
2.4%
点击查看自引率趋势图>
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
23.23%4.63%-
CiteScore：8.30
SJR：1.267
SNIP：0.898
学科类别分区排名百分位
大类：Medicine
小类：Pharmacology (medical)
Q1
35 / 275
大类：Medicine
小类：Pharmacology
Q1
58 / 321

期刊高被引文献

Prostaglandin D2 receptor antagonists in allergic disorders: safety, efficacy, and future perspectives
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1555237
The Jakinibs in systemic lupus erythematosus: progress and prospects
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1551358
Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC)
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1557145
Cannabis for cancer – illusion or the tip of an iceberg: a review of the evidence for the use of Cannabis and synthetic cannabinoids in oncology
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1561859
Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2018.1558202
Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1597053
BRAF kinase inhibitors for treatment of melanoma: developments from early-stage animal studies to Phase II clinical trials
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1558442
Clinical drug development for dementia with Lewy bodies: past and present
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1681398
Investigational IGF1R inhibitors in early stage clinical trials for cancer therapy
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1694660
New drugs under investigation for the treatment of alopecias
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1568989
Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1657825
Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1678583
RX-3117 (fluorocyclopentenyl cytosine): a novel specific antimetabolite for selective cancer treatment
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1583742
Emerging oral VEGF inhibitors for the treatment of renal cell carcinoma
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1559296
Investigational drugs for the treatment of binge eating disorder (BED): an update
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1692813
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1605354
BIIB093 (IV glibenclamide): an investigational compound for the prevention and treatment of severe cerebral edema
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1681967
Alzheimer’s disease: future drug development and the blood-brain barrier
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1627325
New drugs in early-stage clinical trials for allergic rhinitis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1571581
Siponimod in the treatment of multiple sclerosis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1676725
Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1555236
Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1627326
New developments in investigational HDAC inhibitors for the potential multimodal treatment of cachexia
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1557634
The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1650019
Investigational CHK1 inhibitors in early phase clinical trials for the treatment of cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1694661
Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1667332
Defining and targeting wild-type BRCA high-grade serous ovarian cancer: DNA repair and cell cycle checkpoints
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1657403
The molecular basis for current targets of NASH therapies
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703949
TTP399: an investigational liver-selective glucokinase (GK) activator as a potential treatment for type 2 diabetes
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1654993
Emerging drugs in randomized controlled trials for sickle cell disease: are we on the brink of a new era in research and treatment?
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703947
Investigational drugs for the treatment of acute myocardial infarction: focus on antiplatelet and anticoagulant agents
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1559814
Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1581763
Ridinilazole for the treatment of Clostridioides difficile infection
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1582640
Current advances in BCG-unresponsive non-muscle invasive bladder cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1655730
Mucinous ovarian cancer: current therapeutic targets, preclinical progress, and experimental drugs
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1693999
Co-crystal of tramadol-celecoxib: preclinical and clinical evaluation of a novel analgesic
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1612557
Drugs under development for the treatment of functional dyspepsia and related disorders
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1673365
Emerging patient-specific treatment modalities in head and neck cancer – a systematic review
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1582642
Future directions in endometriosis treatment: discovery and development of novel inhibitors of estrogen biosynthesis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1618269
Hepatocellular carcinoma: an update on investigational drugs in phase I and II clinical trials
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1677606
Clinical profile of the functionally selective glucocorticoid receptor agonist BI 653048 in healthy male subjects
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1599859
Investigational drugs currently in phase II clinical trials for actinic keratosis
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1636030
Investigational fibroblast growth factor receptor 2 antagonists in early phase clinical trials to treat solid tumors
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1672655
Genomics in non-adenoid cystic group of salivary gland cancers: one or more druggable entities?
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1598376
What can independent research for mesothelioma achieve to treat this orphan disease?
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1638363
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1696772
Etripamil nasal spray: an investigational agent for the rapid termination of paroxysmal supraventricular tachycardia (SVT)
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703180
Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1648430
Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2020.1703948
Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents
来源期刊：Expert Opinion on Investigational DrugsDOI：10.1080/13543784.2019.1692811

相关文章

Materials Today Bio解析：IF=8.7，8天初审
2025-11-25
《ZEITSCHRIFT FUR GEBURTSHILFE UND NEONATOLOGIE》德国老牌产科期刊免版面费、非预警，毕业保底首选！
2025-11-25
Journal of Multidisciplinary Healthcare：IF= 2.4，中科院3区，JCR Q2，多学科综合医学开放获取期刊，应用性强，审稿迅速，编辑反馈专业！
2025-10-15
European Journal of Medical Genetics：IF= 1.7，中科院4区，JCR Q3，医学遗传学期刊，涵盖分子遗传学、临床基因诊断与罕见病研究，欧洲地区影响力较稳，国际传播适中！
2025-10-15
ANNALS OF ONCOLOGY：中科院1区，肿瘤学，接受率为25%
2025-10-15
Journal of Cystic Fibrosis：权威官方背景，高影响力，整体周期约 3 个月，部分 1 天录用
2025-10-15
JOURNAL OF INHERITED METABOLIC DISEASE：影响因子平稳，学术认可度高，年发文稳定，4个月录用
2025-10-15
JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE：自引风险小，审稿周期短，发表难度低，但if持续下降
2025-10-15
Neurobiology of Stress：中科院 2 区，认可度高，国人发文第二，机会公平
2025-10-15
NATURE REVIEWS DRUG DISCOVERY：中科院1区，生物工程与应用微生物，药学，接受率为21%
2025-10-15

期刊推荐

AAPS Journal封面

AAPS Journal

学科领域：医学
影响因子：3.7
中科院分区： 3区
AAPS PHARMSCITECH封面

AAPS PHARMSCITECH

学科领域：医学
影响因子：4
中科院分区： 3区
Academic Pediatrics封面

Academic Pediatrics

学科领域：医学
影响因子：2.8
中科院分区： 3区
ACTA ANAESTHESIOLOGICA SCANDINAVICA封面

ACTA ANAESTHESIOLOGICA SCANDINAVICA

学科领域：医学
影响因子：2
中科院分区： 3区
论文发表 2-4个月录用 7500+文章录用 不成功可退款
新
2026年3月发布（新锐分区）
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
3区
否
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学3区
PHARMACOLOGY & PHARMACY 药学
2区
否
是
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学2区
PHARMACOLOGY & PHARMACY 药学
2区
否
是